Finite-course ocrelizumab in relapsing multiple sclerosis: Results of two prospective open-label trials with matched controls. Salazar-Camelo A, Vega L, Fadlallah Y, Bou Rjeily N, et al. Mult Scler 2025 Sep 19:13524585251375350. doi: 10.1177/13524585251375350.

Read + Share

Amedeo Smart

Independent Medical Education

Salazar-Camelo A, Vega L, Fadlallah Y, Bou Rjeily N, et al. Finite-course ocrelizumab in relapsing multiple sclerosis: Results of two prospective open-label trials with matched controls. Mult Scler 2025 Sep 19:13524585251375350. doi: 10.1177/13524585251375350.
PMID: 40970353